The Carolina Breast Cancer Study (CBCS) Phase III is a continuation of a successful SPORE-supported population-based study examining genetic and epidemiologic risk factors and characteristics of breast cancer with a focus on African-American (AA) and premenopausal breast cancer. Studies from the approximately 2000 breast cancer patients participating in CBCS Phases I and II demonstrated that patients with AA race and young age had a high prevalence ofthe poor prognosis Basal-like breast cancer, and conversely a low prevalence ofthe good prognosis Luminal A subtype. Additionally, reevaluafion of traditional risk factors suggested considerable heterogeneity in effects by subtype;unique genetic and lifestyle factor associations have been observed for basal-like breast cancer, sometimes with effects in the opposite direction as expected based on associations with overall breast cancer risk. Based on these results, we hypothesize that the higher incidence and mortality from breast cancer in younger African American women compared to white women is due to a combination of factors, including differences in tumor biology, access to care, and type of treatment received. Furthermore, we hypothesize that continued comprehensive investigation of these factors will identify specific clinical and public health interventions to lower breast cancer mortality. To identify the factors that are associated with each breast cancer subtype, CBCS Phase III was opened in 2008, expanding the previous 24-county catchment area of Phases l-ll to 44 counties across North Carolina, and will accrue an additional 1500 AA women and 1500 non-AA women by 2014. The goal of CBCS III is to identify determinants of disparities in breast cancer clinical outcomes, including biologic, racial, socioeconomic, behavioral factors, and to identify modifiable factors in clinical care (delivery and access) that address the causes of disparities. CBCS Phase III is beyond the scope of a single funding source and is broadly supported by the University and other mechanisms, however there are crucial translational implications of this project. Specifically, SPORE funding for gene expression profiling on the tumors (Aim 1), which will enable evaluation of differences in risk factors distribution by subtype (Aim 2), and will be used for collection of treatment and outcome data to assess survival outcomes (Aim 3). This study will provide a comprehensive picture ofthe biology and epidemiology of breast cancer and breast cancer disparities, from risk to survival.
Examination of factors affecting risk, behavior, and prognosis within and across tumor subtypes, and between AA and non-AA women, will identify determinants of racial disparities in breast cancer risk and outcome.
|Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987|
|Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:|
|Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829|
|Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383|
|Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39|
|Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820|
|Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701|
|Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330|
|Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86|
|Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304|
Showing the most recent 10 out of 598 publications